NASDAQ · BEAT
Healthcare · Medical - Healthcare Information Services
$0.49
Up+$0.02 (+3.14%)
Updated Aug 23, 2026, 6:15 AM
SID Score
3.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
BEAT does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
The latest Smart Investors Daily articles mentioning BEAT.
BEAT research
Company profile and research snapshot.
HeartBeam Inc is a medical technology company is focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company's ability to develop higher-resolution ECG solutions is achieved through the development of the Company's proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 14, 2026 | Maxim Group | Buy | — |
| May 22, 2026 | HC Wainwright & Co. | Buy | — |
| May 15, 2026 | Benchmark | Speculative Buy | — |
| Mar 31, 2026 | B. Riley Securities | Buy | — |
| Mar 30, 2026 | D. Boral Capital | Buy | — |
No generated briefing is available yet.
Benzinga · Aug 14, 2026
On August 14, 2026, HeartBeam, Inc. (the "Company"), entered into an At-The-Market Equity Offering Sales Agreement (the "Sales Agreement") with Titan Partners Securities LLC, as sales agent, pursuant to
Benzinga · Aug 13, 2026
HeartBeam (NASDAQ:BEAT) held its second-quarter earnings conference call on Thursday. Below is the complete transcript from the call. Benzinga APIs provide real-time access to earnings call transcripts and financial
ChartMill · Jul 16, 2026
After the closing bell on Thursday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session.
Benzinga · Jul 14, 2026
Maxim Group analyst Anthony Vendetti initiates coverage on HeartBeam (NASDAQ:BEAT) with a Buy rating and announces Price Target of $2.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning BEAT.
